ArticleFrontiers in oncology2022

Real-world experience with anti-programmed cell death protein 1 immunotherapy in patients with esophageal cancer: A retrospective single-center study.

Xinpeng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.